Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fasting Conditions
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The study was conducted as an open-label, balanced, randomized, two-treatment, two-period,
two-sequence, single-dose, crossover, bioequivalence study comparing Minocycline
hydrochloride extended release tablets 135 mg manufactured by OHM Laboratories Inc. with
SolodynTM extended release tablets 135 mg manufactured by AAI Pharma, Inc Wilmington, NC
28405 and manufactured for Medicis, The Dermatology Company Scottsdale, AZ 85258 in healthy,
adult, male, human subjects under fasting condition.